A Postmarketing Study of LEQEMBI in South Korean Participants With Alzheimer's Disease

Recruiting now

Conditions studied: Alzheimer's Disease

In brief

The primary purpose of this study is to evaluate safety of LEQEMBI in the real-world clinical setting as reported by events of amyloid-related imaging abnormalities (ARIA)-edema (ARIA-E), ARIA-hemosiderin deposition (ARIA-H), symptomatic ARIA-E, symptomatic ARIA-H, and intracerebral hemorrhage (ICH) greater-than 1 centimeter (cm) in patients treated with LEQEMBI.

Key facts

Study ID

NCT06810960

Run by

Eisai Korea Inc.

People needed

3000

Starts

2025-02-24

Expected to finish

2029-09-30

Last updated by the study team

2026-04-21

Who can join

Age: 19 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Enrolled in JOY-ALZ before the decision to treat with LEQEMBI
• The clinical decision to treat with LEQEMBI has already been made
• Provides written informed consent for the use of medical information to be shared with Eisai Korea Inc.

You may not qualify if…

• Currently participating in an interventional clinical study

Where it is running

• Eisai Trial Site #1 — Nutley, New Jersey, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.